Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Nonclinical and Clinical Pharmacogenomics: The New Frontier—Premiere Event of the Predictive Toxicology Discussion Group

Nonclinical and Clinical Pharmacogenomics: The New Frontier—Premiere Event of the Predictive Toxicology Discussion Group

Monday, November 14, 2005

The New York Academy of Sciences

Presented By


Organizers: William Pennie, Pfizer; and Donna Mendrick, Gene Logic

We are proud to announce the premiere event of the Predictive Toxicology Discussion Group. This group is the most recent addition to the Frontiers of Science Program.

The aim of the Predictive Toxicology Discussion Group is to bring experts from basic research together with toxicologists, traditionally based in development, to accelerate the adoption of new techniques that may increase the predictive power of toxicology studies. Leading scientists working at the forefront of their discipline will discuss their research and how application of the latest advancements in science can improve the pace of technological advancement in toxicology.

By providing a neutral forum for the active collaboration of toxicologists with their cross-disciplinary colleagues, this group expects the future of toxicology to have increased generation of faster, low-cost, high-throughput assays; better prediction of toxic responses; and an improved understanding of the underlying molecular mechanisms contributing to a toxic response.

Program committee: Matthew S. Bogdanffy, Boehringer Ingelheim; Rakesh Dixit, Merck; Michael Gallo, Rutgers University; Donald N. Halbert, Iconix; Supriya Jayadev, Boehringer-Ingelheim; Zaid Jayyosi, Aventis; Lois Lehman-McKeeman, Bristol-Myers Squibb; Gregg R. Lundeen, Eli Lilly and Company; Donna L. Mendrick, GeneLogic; William Pennie, Pfizer; James L. Stevens, Eli Lilly and Company; and Mike Thibodeau, Boehringer Ingelheim


3:00 PM–5:15 PM: Presentations

Wayne Rosenkrans, AstraZeneca
"The Impact of Personalized Medicine."

Michael Lawton, Pfizer
"Measuring Gene Expression in Blood Vessels: The Challenges of Applying Toxicogenomics to Drug-Induced Vascular Injury."

Donna Mendrick
, Gene Logic
"Pharmacogenomic Biomarker Discovery."

Coffee Break

Alexandra Heinloth, National Institute of Environmental Health Sciences
"Genomic Detection of Incipient Acetaminophen Toxicity in Blood."

5:15 PM–6:15 PM: Panel Discussion

Reception to follow.


"The Impact of Personalized Medicine"
Wayne Rosenkrans
Rapid changes in the scientific and commercial environment are forcing several industries, including pharma, to examine new business models. The classic model of using marketing throw weight to promote products with modest therapeutic benefit to an increasingly sophisticated and skeptical customer is coming under increasing fire from consumers, providers, payers, and regulators concerned about the cost of health care. Even the very foundation of the research-based pharma industry, that innovation in medicine is valued, has been called into question recently in the wake of large product withdrawals. The industry must reshape its value equation, away from one size fits all, and move toward a sense of appropriate pharmaceutical care—the concept of "the right therapy, for the right patient, at the right dose, the first time." Personalized medicine (PM) represents the necessary juxtaposition of science, medicine, and commercial opportunity to move in this direction. But with the promise of PM comes a need for new business models, new strategies for profitability, new challenges in development, and new policy issues.
-What are the changing definitions of PM going forward? and What are the public policy issues surrounding PM?
-What should the new mental model of product success be?
-What are the challenges of understanding the new market and convincing consumers of value?